Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Icariin-conditioned serum (ICS) is an experimental biological preparation used in Traditional Chinese Medicine research to evaluate the therapeutic potential of icariin and its metabolites under conditions that mimic in vivo metabolism. It is produced by collecting blood serum from animals, such as rats or rabbits, following the oral administration of icariin, a prenylated flavonoid derived from the *Epimedium* plant species. This method, known as serum pharmacology, ensures that the experimental medium contains not only the parent compound but also its bioactive metabolites (e.g., icariside II) and potentially induced endogenous factors. In musculoskeletal research, ICS is investigated for its ability to promote chondrocyte proliferation, inhibit inflammatory cytokines, and regulate subchondral bone remodeling. It is frequently studied in the context of osteoarthritis and cartilage repair, often delivered locally via tissue engineering scaffolds like thiolated chitosan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on icariin-conditioned serum.